Loss of treatment benefit due to low compliance with bisphosphonate therapy

Author： Penning-van Beest F.   Erkens J.   Olson M.   Herings R.  

Publisher： Springer Publishing Company

ISSN： 0937-941X

Source： Osteoporosis International, Vol.19, Iss.4, 2008-04, pp. : 511-517

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

What Predicts Early Fracture or Bone Loss on Bisphosphonate Therapy?

By Sawka Anna M.   Adachi Jonathan D.   Ioannidis George   Olszynski Wojciech P.   Brown Jacques P.   Hanley David A.   Murray Tim   Josse Robert   Sebaldt Rolf J.   Petrie Annie   Tenenhouse Alan   Papaioannou Alexandra   Goldsmith Charlie H.  

Journal of Clinical Densitometry, Vol. 6, Iss. 4, 2003-12 ,pp. : 315-322

Humana Press, Inc

Access to resources Recommend Favorite

Bisphosphonate Therapy is Effective in the Treatment of Sacral Giant Cell Tumor

By  

Oncology Research and Treatment, Vol. 34, Iss. 12, 2011-11 ,pp. : 702-704

Karger

Access to resources Recommend Favorite

Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy

By Gold Deborah T.   Trinh Haian   Safi Wael  

Current Medical Research and Opinion, Vol. 25, Iss. 8, 2009-08 ,pp. : 1831-1839

Informa Healthcare

Access to resources Recommend Favorite

Treatment Compliance and Early Termination of Therapy: A Comparative Study

By  

Psychotherapy and Psychosomatics, Vol. 75, Iss. 2, 2006-03 ,pp. : 113-121

Karger

Access to resources Recommend Favorite

Oral bisphosphonate compliance and persistence: a matter of choice?

By Silverman S.   Schousboe J.   Gold D.  

Osteoporosis International, Vol. 22, Iss. 1, 2011-01 ,pp. : 21-26

Springer Publishing Company

Access to resources Recommend Favorite